Prior Auth Approval Odds by Insurer: What 2026 Data Shows

The Prior Auth Approval Landscape in Mid-2026

Prior authorization is the gatekeeper between your prescriber's clinical decision and your insurance company's willingness to pay. For GLP-1 medications, PA is nearly universal — even plans that cover these medications require documentation before approving coverage.

Approval rates are difficult to pin down precisely because insurers don't publish them, and the data that exists comes from prescriber surveys, PBM reports, and patient advocacy group tracking. What we can describe with reasonable confidence is the pattern: which types of insurers tend to approve more readily, what documentation makes the biggest difference, and how the landscape has shifted in 2026.

Approval Patterns by Insurer Type

Large employer self-insured plans (highest approval rates): Employers who've specifically added anti-obesity medication coverage tend to have the most straightforward PA processes. The plan already made the strategic decision to cover these medications — the PA is confirming eligibility, not deciding coverage philosophy. First-submission approval rates for clinically appropriate patients appear to be 60-80% in these plans.

Commercial fully-insured plans (moderate): Plans from major carriers (UnitedHealthcare, Anthem, Cigna, Aetna, Humana) vary widely depending on the specific plan design purchased by the employer. Some plan tiers include anti-obesity medication coverage; others explicitly exclude it. For plans that cover GLP-1s, first-submission approval rates appear to be 40-60%.

Medicaid managed care (lower, but improving): States that have opted to cover GLP-1s through Medicaid generally have stricter PA criteria — higher BMI thresholds, more step therapy requirements, and specialist referral mandates. First-submission approval rates vary enormously by state and MCO.

Medicare (via GLP-1 Bridge): The Bridge program launched July 1, 2026, so approval rate data is still emerging. The PA process requires prescriber certification of eligibility and lifestyle program participation. Early reports suggest the process is straightforward for patients who clearly meet the eligibility criteria.

What Makes the Difference Between Approval and Denial

Across all insurer types, the factors that most consistently separate approved PAs from denied ones are:

Documentation completeness: The single biggest factor. PAs submitted with full clinical documentation — BMI history, comorbidity records, lab results, prior treatment history, and a physician letter of medical necessity — are approved at dramatically higher rates than sparse submissions.

Step therapy completion: If the plan requires step therapy and the PA demonstrates completed steps, approval follows straightforwardly. If step therapy isn't documented, denial is nearly automatic regardless of clinical appropriateness.

Correct diagnosis coding: Submitting the PA with appropriate ICD-10 codes for both the weight management indication (E66.01 for morbid obesity, E66.09 for other obesity) and any supporting comorbidities improves processing accuracy.

Prescriber specialty: PAs from endocrinologists and obesity medicine specialists tend to be approved at higher rates than those from general practitioners — not because the clinical content is different, but because specialist involvement signals clinical seriousness to the insurer's review process.

Improving Your Personal Approval Odds

Based on the patterns described above, here's how to maximize your specific probability of PA approval:

Build your documentation before the PA is submitted. Don't let your prescriber submit a PA with whatever's currently in your chart. Ask to review the PA packet before submission. Ensure it includes BMI measurements from at least two clinical visits, all relevant comorbidity documentation, recent lab results, and evidence of prior weight management attempts.

Ask your prescriber to include a letter of medical necessity. A detailed, patient-specific letter citing clinical guidelines is the single most impactful addition to a PA submission. Generic letters are less effective than letters that reference your individual health data and treatment history.

Know your plan's specific criteria before submitting. Call your insurer and ask for their clinical policy for anti-obesity medications. This document tells you exactly what criteria the PA reviewer will apply. Share it with your prescriber so the PA addresses every requirement.

Request expedited review if clinically justified. If your health situation includes urgency factors — rapidly worsening comorbidities, upcoming surgery, or clinical deterioration — your prescriber can request an expedited PA review (typically 72-hour turnaround instead of 15-30 days).